Literature DB >> 8925519

p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity, and colon.

W P Bennett1.   

Abstract

Human cancers are believed to develop in multiple stages. There is morphologic evidence for this in many tissues, including cancers of the lung, esophagus, head and neck, skin, colon, cervix, and bladder; and corresponding genetic models are developing. This article summarizes reports describing the timing and frequency of p53 alterations (i.e., mutation and/or protein accumulation) in progenitor lesions of human lung, esophagus (both squamous and Barrett's), head and neck, and colon. In squamous lesions of the lung, esophagus, and head and neck, there is evidence for p53 alteration in a minority of the earliest dysplasias and in a majority of the late or severe dysplasias. It is not known whether all of the alterations are caused by mutations or by epigenetic factors. In sporadic colonic adenomas, there is also evidence for p53 protein accumulation in early adenomas, but it is clear that p53 mutations occur mostly in the stage of late adenoma or carcinoma. The causes of the protein accumulation in the earlier stages are not clear. Strategies for early diagnosis based on detecting p53 mutations in body fluids including sputum, urine, and stool have been published (Sidransky D. J. Natl Cancer Inst 1994; 86:995-956). Although substantial technical hurdles remain, the high frequency and early occurrence of these mutations make the p53 tumor suppressor gene an attractive target for early detection and early therapeutic intervention in many common human cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8925519

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  6 in total

Review 1.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

2.  Excess beta-catenin promotes accumulation of transcriptionally active p53.

Authors:  A Damalas; A Ben-Ze'ev; I Simcha; M Shtutman; J F Leal; J Zhurinsky; B Geiger; M Oren
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

3.  p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.

Authors:  S Garnett; K L Dutchak; R V McDonough; D Dankort
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

4.  Personal and family history of cancer and the risk of Barrett's esophagus in men.

Authors:  N Khalaf; D Ramsey; J R Kramer; H B El-Serag
Journal:  Dis Esophagus       Date:  2014-02-17       Impact factor: 3.429

5.  Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy.

Authors:  S S Yoon; N M Carroll; E A Chiocca; K K Tanabe
Journal:  J Gastrointest Surg       Date:  1999 Jan-Feb       Impact factor: 3.267

6.  Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Authors:  S Zienolddiny; D Ryberg; M O Arab; V Skaug; A Haugen
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.